Table 3.
SNPs nominally associated at P < 0.05 with OS and PFS as prognostic and/or predictive markers in patients with stage II–III colorectal cancer.
| Patients who received OX-based treatment | Patients who received non-OX-based treatment | Interaction terma | ||||
|---|---|---|---|---|---|---|
| Gene - SNP - effect allele | HR (95% CI) | P | HR (95% CI) | P | P | Endpoint |
| Previously reported SNPs | ||||||
| GSTM5 - rs11807 - C | 1.48 (1.02–2.15) | 0.037 | 0.93 (0.73–1.18) | 0.542 | 0.026 | OS |
| GSTM5 - rs11807 - C | 1.52 (1.05–2.20) | 0.028 | 0.91 (0.69–1.21) | 0.522 | 0.026 | PFS |
| ERCC2 - rs13181 - G | 1.17 (0.87–1.58) | 0.295 | 0.80 (0.64–0.97) | 0.022 | 0.041 | OS |
| ERCC2 - rs1799793 - T | 1.32 (0.97–1.79) | 0.080 | 0.81 (0.66–1.00) | 0.048 | 0.016 | OS |
| ERCC5 - rs2016073 - G | 1.48 (1.02–2.14) | 0.038 | 0.95 (0.71–1.27) | 0.720 | 0.032 | PFS |
| XPC - rs2228000 - A | 0.63 (0.42–0.96) | 0.031 | 1.08 (0.84–1.39) | 0.555 | 0.059 | PFS |
| P2RX7 - rs208294 - C | 1.36 (1.01–1.83) | 0.045 | 1.07 (0.88–1.30) | 0.516 | 0.427 | OS |
| P2RX7 - rs208294 - C | 1.63 (1.19–2.24) | 0.002 | 1.00 (0.8–1.26) | 0.983 | 0.096 | PFS |
| HMGB1 - rs1360485 - C | 0.71 (0.48–1.03) | 0.071 | 1.17 (0.92–1.48) | 0.192 | 0.025 | PFS |
| Putative functional SNPs | ||||||
| MGMT - rs12917 - T | 1.37 (0.91–2.07) | 0.131 | 0.71 (0.52–0.96) | 0.029 | 0.012 | OS |
| RPA1 - rs5030755 - G | 1.27 (0.76–2.11) | 0.364 | 0.65 (0.42–1.00) | 0.053 | 0.015 | PFS |
| P2RX7 - rs2230911 - G | 0.42 (0.18–0.97) | 0.043 | 1.42 (0.97–2.06) | 0.069 | 0.006 | OS |
Note: Significant P value marked in bold. The models were adjusted for age, sex, cancer location (proximal vs. distal), and stage for the analyses. The model was also stratified for grade (1–2 vs. 3–4), KRAS mutation (wild type vs. mutation), resection status (completely resected vs. not completely resected), array used for genotyping data to account for violation of proportional hazards assumption.
Abbreviations: ERCC2, ERCC excision repair 2; ERCC5, ERCC excision repair 5, XPC, XPC complex subunit; GSTM5, glutathione S-transferase mu 5; HMGB1, high mobility group box 1; MGMT, O-6-methylguanine-DNA methyltransferase; P2RX7, purinergic receptor P2×7; RPA1, replication protein A1.
aInteraction term between SNP and the type of chemotherapy (oxaliplatin-based vs. others).